更新于：2024-05-01
Cefuroxime Sodium
头孢呋辛钠
更新于：2024-05-01
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C16H16N4O8S |
InChIKeyJFPVXVDWJQMJEE-IZRZKJBUSA-N |
CAS号55268-75-2 |
查看全部结构式(2)
关联
67
项与 头孢呋辛钠 相关的临床试验Efficacy and Safety of Bismuth Quadruple Therapy Containing Cefuroxime and Tetracycline as First-line Therapy for Eradicating Helicobacter Pylori in Patients Allergic to Penicillin: A Multicenter, Randomized Controlled Study
An Open Randomized Controlled Study of Bismuth Quadruple Therapy With Cefuroxime as Rescue Therapy for Helicobacter Pylori Infection
Very Short-course Versus Standard Course Antibiotic Therapy in Patients With Acute ChOlangitis After Adequate Endoscopic BiliaRy drAinage
100 项与 头孢呋辛钠 相关的临床结果
登录后查看更多信息
100 项与 头孢呋辛钠 相关的转化医学
登录后查看更多信息
100 项与 头孢呋辛钠 相关的专利（医药）
登录后查看更多信息
4,659
项与 头孢呋辛钠 相关的文献（医药）2024-02-13Antimicrobial agents and chemotherapy
Sensitizing methicillin-resistant Staphylococcus aureus (MRSA) to cefuroxime: the synergic effect of bicarbonate and the wall teichoic acid inhibitor ticlopidine.
Article
作者: Selvi C Ersoy ; Richard A Proctor ; Warren E Rose ; Wessam Abdelhady ; Sook-Ha Fan ; Sabrina L Madrigal ; Ahmed M Elsayed ; Henry F Chambers ; Rita G Sobral ; Arnold S Bayer
Methicillin-resistant Staphylococcus aureus (MRSA) strains are a major challenge for clinicians due, in part, to their resistance to most β-lactams, the first-line treatment for methicillin-susceptible S. aureus. A phenotype termed "NaHCO3-responsiveness" has been identified, wherein many clinical MRSA isolates are rendered susceptible to standard-of-care β-lactams in the presence of physiologically relevant concentrations of NaHCO3, in vitro and ex vivo; moreover, such "NaHCO3-responsive" isolates can be effectively cleared by β-lactams from target tissues in experimental infective endocarditis (IE). One mechanistic impact of NaHCO3 exposure on NaHCO3-responsive MRSA is to repress WTA synthesis. This NaHCO3 effect mimics the phenotype of tarO-deficient MRSA, including sensitization to the PBP2-targeting β-lactam, cefuroxime (CFX). Herein, we further investigated the impacts of NaHCO3 exposure on CFX susceptibility in the presence and absence of a WTA synthesis inhibitor, ticlopidine (TCP), in a collection of clinical MRSA isolates from skin and soft tissue infections (SSTI) and bloodstream infections (BSI). NaHCO3 and/or TCP enhanced susceptibility to CFX in vitro, by both minimum inhibitor concentration (MIC) and time-kill assays, as well as in an ex vivo simulated endocarditis vegetations (SEV) model, in NaHCO3-responsive MRSA. Furthermore, in experimental IE (presumably in the presence of endogenous NaHCO3), pre-exposure to TCP prior to infection sensitized the NaHCO3-responsive MRSA strain (but not the non-responsive strain) to enhanced clearances by CFX in target tissues. These data support the notion that NaHCO3 is acting similarly to WTA synthesis inhibitors, and that such inhibitors have potential translational applications in the treatment of certain MRSA strains in conjunction with specific β-lactam agents.
2024-02-09Expert review of anti-infective therapy
An assessment of the index of rational drug prescribing for severe acute respiratory infections among hospitalised children in Northern Nigeria: a retrospective study.
Article
作者: Aliyu Sulaiman ; Mohammad Alfa Isah ; Abubakar Usman
BACKGROUND:
This study evaluated drug use pattern among hospitalized children with severe acute respiratory infection (SARI) in Nigeria.
RESEARCH DESIGN AND METHODS:
A retrospective assessment of prescribed medicines for children aged 13 years and below who were admitted and treated for SARI from 1 January 2016 to 31 December 2018 was conducted. The WHO prescribing indicators and the Index of Rational Drug Prescribing were used to evaluate prescriptions.
RESULTS:
A total of 259 patients were included, mostly diagnosed with bronchopneumonia (56%). A summary of WHO-core prescribing indicators showed the average number of drugs per encounter was 3.9, medicines prescribed by generic name was 82.1%, and an encounter with at least an antibiotic was 99.7%. The percentage of drugs prescribed from the Essential Medicine List for children was 79%. The most frequently prescribed pharmacological class of medicines was antibiotics (41.4%). Cephalosporins (40.0%), aminoglycosides (34.1%), and penicillins (21.5%) were the most commonly prescribed antibiotic classes. Gentamicin (34.1%) and cefuroxime (21.5%) were the most commonly prescribed antibiotics.
CONCLUSIONS:
Drug prescribing for hospitalized children with SARI was suboptimal, especially with regard to polypharmacy, antibiotics, and injection use. Interventions to promote rational use of medicines including antimicrobial stewardship interventions are recommended.
2024-02-09The Journal of antimicrobial chemotherapy
Do dietary interventions exert clinically important effects on the bioavailability of β-lactam antibiotics? A systematic review with meta-analyses.
Review
作者: Agnieszka Wiesner ; Paweł Zagrodzki ; Paweł Paśko
BACKGROUND:
Managing drug-food interactions may help to achieve the optimal action and safety profile of β-lactam antibiotics.
METHODS:
We conducted a systematic review with meta-analyses in adherence to PRISMA guidelines for 32 β-lactams. We included 166 studies assessing the impact of food, beverages, antacids or mineral supplements on the pharmacokinetic (PK) parameters or PK/pharmacodynamic (PK/PD) indices.
RESULTS:
Eighteen of 25 β-lactams for which data on food impact were available had clinically important interactions. We observed the highest negative influence of food (AUC or Cmax decreased by >40%) for ampicillin, cefaclor (immediate-release formulations), cefroxadine, cefradine, cloxacillin, oxacillin, penicillin V (liquid formulations and tablets) and sultamicillin, whereas the highest positive influence (AUC or Cmax increased by >45%) for cefditoren pivoxil, cefuroxime and tebipenem pivoxil (extended-release tablets). Significantly lower bioavailability in the presence of antacids or mineral supplements occurred for 4 of 13 analysed β-lactams, with the highest negative impact for cefdinir (with iron salts) and moderate for cefpodoxime proxetil (with antacids). Data on beverage impact were limited to 11 antibiotics. With milk, the extent of absorption was decreased by >40% for cefalexin, cefradine, penicillin G and penicillin V, whereas it was moderately increased for cefuroxime. No significant interaction occurred with cranberry juice for two tested drugs (amoxicillin and cefaclor).
CONCLUSIONS:
Factors such as physicochemical features of antibiotics, drug formulation, type of intervention, and patient's health state may influence interactions. Due to the poor actuality and diverse methodology of included studies and unproportionate data availability for individual drugs, we judged the quality of evidence as low.
100 项与 头孢呋辛钠 相关的药物交易
登录后查看更多信息
研发状态
| 适应症 | 最高研发状态 | 国家/地区 | 公司 |
|---|---|---|---|
| 脓毒症 | 批准上市 | - | |
| 革兰氏阴性菌感染 | 批准上市 | - | |
| 淋病 | 批准上市 | - | |
| 细菌感染 | 批准上市 | 中国 更多 | |
| 呼吸道感染 | 批准上市 | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 窪鹽齋鹽網廠淵繭齋製(廠築獵範鹹範齋鏇衊繭) = 膚憲網壓淵淵選構繭築 構醖繭夢醖顧艱獵繭鏇 (願壓窪艱窪鬱鬱壓繭憲 ) | - | 2016-09-01 | |||
N/A | - | 憲鹹獵窪鏇遞醖餘積淵(壓鏇淵鹹衊夢壓憲鑰襯) = 壓糧獵鹽積餘製鹽遞繭 鑰選鹽襯壓膚憲淵築膚 (繭積範夢餘構衊廠選廠 ) 更多 | - | 2014-04-01 | |||
N/A | 26 | (獵鏇糧顧鑰鬱構膚壓衊) = 網壓夢齋淵製廠艱襯膚 簾艱餘襯衊範觸淵鏇窪 (襯蓋鹽築獵衊觸窪齋範, 0.11) | - | 2019-07-01 | |||
N/A | - | (醖鹹願壓衊鹽衊憲製鏇) = 選鏇繭鬱簾鹹製鹽鏇齋 網獵鹽鏇觸艱顧憲願膚 (鏇遞築鬱鹹鬱憲齋製繭 ) | 积极 | 2019-07-01 | |||
(醖鹹願壓衊鹽衊憲製鏇) = 襯積構構鹹積鹽餘鹽膚 網獵鹽鏇觸艱顧憲願膚 (鏇遞築鬱鹹鬱憲齋製繭 ) | |||||||
临床2期 | 196 | 鹹糧餘夢製積築選膚齋(鑰願齋觸選艱蓋顧願鬱) = 壓繭廠鏇醖鏇選淵築憲 糧積衊鑰繭餘顧鹹繭構 (壓遞鹽範鏇簾窪獵鹹鑰 ) 更多 | 积极 | 2019-02-01 | |||
鹹糧餘夢製積築選膚齋(鑰願齋觸選艱蓋顧願鬱) = 範壓網選膚窪製膚憲製 糧積衊鑰繭餘顧鹹繭構 (壓遞鹽範鏇簾窪獵鹹鑰 ) 更多 | |||||||
N/A | 27 | ICI cefuroxime | (選觸糧獵糧糧選醖鬱範) = 衊構夢範膚築餘鏇壓繭 淵築範遞繭糧觸蓋鹹製 (蓋積壓廠襯願簾糧鹹鹹 ) 更多 | 积极 | 2022-06-01 | ||
Intracameral Cefuroxime | (選觸糧獵糧糧選醖鬱範) = 襯鬱衊簾選淵鏇衊膚鑰 淵築範遞繭糧觸蓋鹹製 (蓋積壓廠襯願簾糧鹹鹹 ) 更多 | ||||||
临床4期 | 84 | 鏇糧構餘壓鹽齋願範獵(網積窪壓艱餘膚衊壓窪) = 願蓋積蓋獵壓醖鹽膚醖 簾遞壓衊廠鹽壓觸獵膚 (糧壓膚鬱廠鹽鑰積窪構, 0.15 ~ 58.3) | - | 2020-07-01 | |||
鏇糧構餘壓鹽齋願範獵(網積窪壓艱餘膚衊壓窪) = 選餘窪繭鹽簾糧觸顧鏇 簾遞壓衊廠鹽壓觸獵膚 (糧壓膚鬱廠鹽鑰積窪構, 0.59 ~ 50.18) | |||||||
N/A | 124 | 糧夢簾獵鑰醖積築遞蓋(繭鬱襯獵繭網鏇醖選淵): OR = 3.69 (95% CI, 1.175 ~ 11.607) | - | 2023-02-01 | |||
N/A | - | Without cefuroxime | 艱選築鹽蓋壓獵鑰網窪(構鏇衊構壓衊餘鹹鬱繭) = 壓製繭鏇顧願積憲餘窪 積鏇窪壓淵鹹餘獵醖壓 (構壓齋壓鬱衊廠餘蓋築 ) | 不佳 | 2013-11-18 | ||
艱選築鹽蓋壓獵鑰網窪(構鏇衊構壓衊餘鹹鬱繭) = 淵鬱壓遞選糧鹽觸醖繭 積鏇窪壓淵鹹餘獵醖壓 (構壓齋壓鬱衊廠餘蓋築 ) | |||||||
N/A | - | (築衊襯廠餘網築觸簾構) = 蓋鏇憲遞鹽憲艱淵醖壓 簾壓鑰餘簾遞夢製積願 (顧窪範選夢鏇鹹選製網 ) | 积极 | 2014-10-19 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用